Significantly decreased p27 expression in endometrial carcinoma compared to complex hyperplasia with atypia (correlation with p53 expression)

Pathology and Oncology Research

Volumn 10, Issue 2, 2004, Pages 89-97

  Kacar Özkara, Sevgiye ^a,b   Corakci, Aydin ^a  

^a KOCAELI UNIVERSITY   (Turkey)

^b Mustafa Pasa Mahallesi   (Turkey)

Author keywords

Carcinoma; Endometrium; Hyperplasia; p27; p53

Indexed keywords

AVIDIN; MONOCLONAL ANTIBODY; PARAFFIN; PROTEIN P27; PROTEIN P53; STREPTAVIDIN;

ADULT; AGED; ARTICLE; CANCER GRADING; CARCINOGENESIS; CELL HYPERPLASIA; CELL PROLIFERATION; CELL SECRETION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE;

EID: 3142770434     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02893462     Document Type: Article

References (22)

1. Al Kushi A, Lim P, Aquino-Parsons C, et al: Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium. Mod Pathol 15: 365-371, 2002
2. Bamberger AM, Riethdorf L, Milde-Langosch K, et al: Strongly reduced expression of the cell cycle inhibitor p27 in endometrial neoplasia. Virchows Arch 434: 423-428, 1999
3. Berchuck A, Kohler MF, Marks JR, et al: The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 170: 246-252, 1994
4. Cinel L, Polat A, Aydin Ö, et al: Bcl-2, iNOS, p53 and PCNA expression in normal, disordered proliferative, hyperplastic and malignant endometrium. Pathology International 52: 384-389, 2002
5. Dubowy RL, Feinberg RF, Keefe DL, et al: Improved endometrial assessment using cyclin E and p27. Fertil Steril 80: 146-156, 2003
6. Elhafey AS, Papadimitriou JC, El-hakim MS, et al: Computerized image analysis of p53 and proliferating cell nuclear antigen expression in benign, hyperplastic and malignant endometrium. Arch Pathol Lab Med 125: 872-879, 2001
7. Enomoto T, Fujita M, Inoue M, et al: Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Research 53: 1883-1888, 1993
8. Erdem O, Erdem M, Dursun A, et al: Angiogenesis, p53, and bcl-2 expression as prognostic indicators in endometrial cancer: comparison with traditional clinicopathologic variables. Int J Gynecol Pathol 22: 254-260, 2003
9. Kaku T, Kamura T, Hirakawa T, et al: Endometrial carcinoma associated with hyperplasia - Immunohistochemical study of angiogenesis and p53 expression. Gynecol Oncol 72: 51-5, 1999
10. Kato N, Watanabe J, Jobo T, et al: Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance. J Cancer Res Clin Oncol 129: 222-226, 2003 (Epub 2003 Apr 08]
11. Kimura F, Watanabe J, Hata H. et al: PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. J Cancer Res Clin Oncol [Epub ahead of print], 2003 Dec 20
12. Li SF, Shiozawa T, Nakayama K, et al: Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma. Cancer 77: 321-9, 1996
13. Masciullo V, Susini T, Zamparelli A, et al: Frequent loss of expression of the cyclin-dependent kinase inhibitor p27(Kip1) in estrogen-related endometrial adenocarcinomas. Clin Cancer Res 9: 5332-5338, 2003
14. Miturski R, Semczuk A, Tomaszewski J, et al: Bcl-2 protein expression in endometrial carcinoma: the lack of correlation with p53. Cancer Letters 133: 63-69, 1998
15. Oshita T, Shigemasa K, Nagai N, et al: p27, cyclin E, and CDK2 expression in normal and cancerous endometrium. Int J Oncol 21: 737-743, 2002
16. Saegusa M, Machida D, Okayasu I: Age-dependent differences in tumor cell polarity in endometrial carcinomas. J Cancer Res Clin Oncol 128: 205-213, 2002
17. Shiozawa T, Horiuchi A, Kato K, et al: Up-regulation of p27Kip1 by progestins is involved in the growth suppression of the normal and malignant human endometrial glandular cells. Endocrinology 142: 4182-4188, 2000
18. Shiozawa T, Nikaido T, Nakayama K, et al: Involvement of cyclin-dependent kinase inhibitor p27Kip1 in growth inhibition of endometrium in the secretory phase and of hyperplastic endometrium treated with progesterone. Mol Hum Reprod 4: 899-905, 1998
19. Siufi AA, Cotrim G, Da Silva ID, et al: Effects of tamoxifen therapy on the expression of p27 protein in the endometrium of women with primary breast cancer. Int J Oncol 23: 1545-1551, 2003
20. Suzuki C, Matsumoto T, Sonoue H, et al: Prognostic significance of the infiltrative pattern invasion in endometrioid adenocarcinoma of the endometrium. Pathol Int 53: 495-500, 2003
21. Watanabe J, Sato H, Kanai T, et al: Paradoxical expression of cell cycle inhibitor p27 in endometrioid adenocarcinoma of the uterine corpus - correlation with proliferation and clinicopathological parameters. Br J Cancer 87: 81-85, 2002
22. Zhuang YH, Sarca D, Weisz A, et al: Cell type-specific induction of cyclin D and cyclin-dependent kinase inhibitor p27(kip1) expression by estrogen in rat endometrium. J Steroid Biochem Mol Biol 78: 193-199, 2001